A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.
Epistemonikos ID: aaa685e3eedab9aaef4c239270eb05d0f952ff1e
First added on: Oct 27, 2026